Supernus Announces Issuance of Sixth U.S. Patent Protecting Trokendi XR(R)
"We are very serious about securing intellectual property protection for our innovative products. We will continue to build our patent estate to provide our products with the protection they are entitled to. We now have patent protection on Oxtellar XR® and Trokendi XR® through four and six issued U.S. patents, respectively," said
Supernus has several additional patent applications for extended-release topiramate and extended-release oxcarbazepine pending in other geographic regions.
About Trokendi XR
Trokendi XR is the first approved novel once-daily extended release formulation of topiramate for the treatment of epilepsy. Trokendi XR is an antiepileptic drug indicated for initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures; adjunctive therapy in patients 6 years of age and older with partial onset or primary generalized tonic-clonic seizures; and adjunctive therapy in patients 6 years of age and older with seizures associated with Lennox-Gastaut syndrome. The product is available in 25mg, 50mg, 100mg and 200mg extended-release capsules.
For full prescribing and safety information, click here.
About
Forward Looking Statements
This press release contains forward-looking statements regarding the potential of Trokendi XR and Oxtellar XR and intellectual property protection. Actual results may differ materially from those in these forward-looking statements as a result of various factors, including, but not limited to, risks regarding the company's ability to commercialize the product successfully, whether physicians will prescribe and patients will use the product, and competition in the market. For a further description of these and other risks facing the Company, please see the risk factors described in the Company's Annual Report Form 10-K that was filed with the
CONTACT:Source:Jack A. Khattar , President and CEOGregory S. Patrick , Vice President and CFOSupernus Pharmaceuticals, Inc. Tel: (301) 838-2591 Or INVESTOR CONTACT:Peter Vozzo Westwicke Partners Office: (443) 213-0505 Mobile: (443) 377-4767 Email: peter.vozzo@westwicke.com
News Provided by Acquire Media